Abstract:Obinna O Oleribe, 1, 2 Andrew W Taylor-Robinson, 3, 4 Okey C Nwanyanwu, 5 Marsha Y Morgan, 6 Simon D Taylor-Robinson 7, 8 1 Office of the Director-General, Nigerian Institute for Medical Research, Lagos, Nigeria; 2 Best Health Consult Limited Liability Company, Orange, CA, USA; 3 College of Health Sciences, VinUniversity, Hanoi, Vietnam; 4 Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 5 Fast Forward Africa Limited Liability Company, Austin, TX, USA; 6 Division of Medicine, Royal Free Campus, University College London, London, UK; 7 Departments of Medicine & Public Health, Busitema University, Mbale, Uganda; 8 Department of Surgery and Cancer, Imperial College London, St Mary's Hospital Campus, London, UK Correspondence: Simon D Taylor-Robinson, Email Four years after the first case of COVID-19, the world is still determining how best to prevent and control the long-term effects of SARS-CoV-2 infection. Non-pharmaceutical interventions (NPIs) were employed at the start of the pandemic as the only available options, prior to effective vaccines and antiviral agents. The World Health Organization recommended dual vaccination for 70% worldwide as the threshold for a return to "normal" community life. Immunization rates needed to increase in all global regions, irrespective of socioeconomic status, necessitating more equitable access. During the pandemic, wealthier countries hoarded vaccine supplies even when their citizens were immunized. This highlights the already enormous difficulties in healthcare provision faced by low-income sub-Saharan African countries, which remain at risk as industrialized nations have progressed to a post-pandemic era. Thus, in addition to redoubling vaccination efforts public health policymakers should consider ongoing and future use of NPIs. In this narrative account, we advocate that various NPI practices should not be shelved; rather, more research is needed to evaluate their impact in parallel with booster vaccination. This especially applies to so-called "long COVID". Lessons learned from implementing best practices in resource-limited settings should be incorporated into preparedness guidelines for future infectious disease outbreaks. Keywords: sub-Saharan Africa, COVID-19, health inequality, non-pharmaceutical interventions, pandemic, vaccination Much has been written on the global pandemic caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection. 1–4 SARS-CoV-2, in common with two other pathogenic human respiratory coronaviruses, SARS-CoV and MERS-CoV, tends to cause symptoms at the severe end of the respiratory disease spectrum. 5,6 By comparison, infections with four other coronaviruses, HKU1, NL63, 229E and OC43, generally produce much milder symptoms, often referred to as the "common cold". 7 With the initial emergence of human SARS-CoV-2 infections in December 2019, subsequently termed "coronavirus disease 2019" (COVID-19), the first response of governments around the world was to try to prevent and control viral transmission through public health interventions. 8 Efforts escalated as the virus spread from China to Western Europe and North America in January 2020, with African cases following shortly afterwards. 9 When the World Health Organization (WHO) declared COVID-19 to be a "public health emergency of international concern" on January 30, 2020, 10 and then on March 11, 2020, confirmed that the world was facing a pandemic, 11 the global strategy focused first on disease prevention and later on accelerated development of vaccines and antiviral agents. 6 In the interim, most countries adopted hastily arranged interventions, whereby national borders were closed, air travel was suspended, schools and offices were shut, and remote working and learning were promoted. 12,13 The introduction of personal protective measures meant that people across sub-Saharan Africa and other parts of the world were asked to wear masks, wash their hands frequently or to use hand sanitizers, maintain social distancing, stay at home wherever possible, avoid hand-to-face contact and minimize socialization with others, including shaking hands and other more intimate greetings. 14–19 In addition, screening policies were implemented in Africa using newly developed viral antigen testing; exposed individuals were required to quarantine and those testing positive were asked to self-isolate if it was clinically safe to do so. 7,15,17 Those who developed more severe symptoms were either treated in isolation centres or referred to public and pr -Abstract Truncated-

Time to SARS‐CoV‐2 clearance in African, Caucasian, and Asian ethnic groups

Clinical Characteristics and Factors Associated with Long-Term Viral Excretion in Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study

Four Years Since COVID-19 Day Zero: A Time to Evaluate Past and Future Pandemic Control Policies and Practices in Sub-Saharan Africa?

Delayed Clearance of Viral RNA in Sputum for Severity COVID-19 Patients with Initial High Viral Load

High SARS-CoV-2 seroincidence but low excess COVID mortality in Sierra Leone in 2020-2022

SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency

Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: a prospective cohort study

Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study

High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses

SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali

Post-Omicron SARS-CoV-2 serostatus in Sierra Leone: A cross-sectional study in a maternity hospital setting in Freetown, November/December 2022

Ethnic and racial differences in self-reported symptoms, health status, activity level, and missed work at 3 and 6 months following SARS-CoV-2 infection

SARS-CoV-2 Infection, Hospitalization, and Associated Factors Among People Living With HIV in Southeastern China From December 2022 to February 2023: Cross-Sectional Survey

Screening and Whole Genome Sequencing of SARS-CoV-2 Circulating During the First Three Waves of the COVID-19 Pandemic in Libreville and the Haut-Ogooué Province in Gabon

SARS-CoV-2 Neutralizing Antibodies in Three African Countries Following Multiple Distinct Immune Challenges

Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study

Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey

Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation

SARS-CoV-2 infection and antibody seroprevalence in routine surveillance patients, healthcare workers and general population in Kita region, Mali: an observational study 2020-2021

Clinical progression of patients with COVID-19 in Lagos State, Nigeria

SARS-CoV-2 seropositivity in African women living with HIV and their infants